Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06368076
Other study ID # H-23065096
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 9, 2024
Est. completion date January 2025

Study information

Verified date April 2024
Source Rigshospitalet, Denmark
Contact Sophia Frølich, stud.med
Phone + 45 3545 3561
Email sophia.vera.froelich.01@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with spinal muscular atrophy who are wheelchair users often experience lower back - and gluteal pain, reduced sleep quality, constipation and reduced quality of life - symptoms that regular exercise could potentially alleviate. However, only very little research has been done on exercise for patients who are wheelchair users. The aim of this study is to explore the impact of cycle exercise on patients with spinal muscular atrophy.


Description:

Spinal muscular atrophy (SMA) is a neuromuscular disease affecting the motor neurons of the spinal cord that innervate the skeletal muscles, leading to progressive muscle atrophy and weakness. Consequently, many patients end up having to use a wheelchair from an early age. Besides the impaired motor function, patients with SMA can also experience a variety of symptoms associated with their disease, a sedentary lifestyle and physical inactivity such as lower back and leg pain, obstipation, reduced sleep quality and impacted quality of life. Training can help alleviate these symptoms in patients with neuromuscular diseases. However, there isnĀ“t any validated way for patients with SMA to train as of today. Research has shown that high-intensity interval training (HIIT) has been well tolerated among patients with SBMA, a disease resembling SMA with patients tolerating this form for training well. The aim of this study is to investigate:(1) if HIIT could be exercise modality in SMA patients (2) and to see what positive effects exercise has for their impaired motor function and related challenges. The investigators will test the participants at baseline, which will be followed by a 8-week control period. After the control period the participants will be tested again before the intervention period. During the intervention period the participants will have to train 5 times a week for 10 minutes. After the intervention period, there will be a final test day, where the final results will be compared with those from the baseline.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date January 2025
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 15 Years and older
Eligibility Inclusion Criteria: - Spinal muscular atrophy - Age: over 15 years Exclusion Criteria: - Competing disorders (as arthritis) or other muscle disorders as well as heart- or lung related issues. - Current psychiatric treatment - Unable to use the cycle ergometer due to contractures

Study Design


Intervention

Behavioral:
Exercise
High intensity interval training on a bike or pedaltrainer from the wheelchair.

Locations

Country Name City State
Denmark Rigshospitalet Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Questionnaire on fatigue The Multidimensional Fatigue Inventory (MFI-20) will be used. It measures fatigue in 5 different domains comprised of 4 items each with values ranging from 1 to 5. A higher score indicates more fatigue. Each domain is scored individually, ranging from 4 points (best outcome) to 20 points (worst outcome). 5 minutes
Primary Questionnaire on pain. A visual pain score for leg and lower back pain with 3 questions with scores ranging from 1 to 10 each, 10 being the worst pain imaginable, will be used. 5 minutes
Primary Questionnaire on constipation A questionnaire made from the Danish definition of constipation will be used. Four questions will be answered "yes" or "no". 5 minutes
Primary Questionnaire on quality of life A QoL that has been used in former studies will be used. 16 questions with scores ranging from 1 (very unsatisfied) to 7 (very satisfied) will be scored. 10 minutes
Primary Questionnaire on sleep quality Minimum Score = 0 (better); Maximum Score = 21 (worse) Interpretation: TOTAL < 5 associated with good sleep quality TOTAL > 5 associated with poor sleep quality Minimum Score = 0 (better); Maximum Score = 21 (worse) Interpretation: TOTAL < 5 associated with good sleep quality TOTAL > 5 associated with poor sleep quality Minimum score is 0, maximum score is 21. Total over 5 is associated with good sleep quality and under 5 associated with poor sleep quality. 10 minutes
Secondary Blood sample Change in blood sample for blood lipids, mmol/l 2 minutes
Secondary Blood sample Change in blood sample for HbA1C, mmol/mol 2 minutes
Secondary Blood sample Change in blood sample for Creatine kinase, U/I. This will be monitored before, in the middle and after the exercise period as a safety measure. 2 minutes
Secondary Blood sample Change in blood sample for fasting blood glucose, in mmol/L 2 minutes
Secondary Blood sample Change in blood sample for fasting insulin, in pmol/L. 2 minutes
Secondary Blood sample Change in blood sample for fasting c-peptide, in pmol/L. 2 minutes
Secondary Blood sample Change in blood sample for ALT (liver parameter) in U/L 2 minutes
Secondary Blood sample Change in blood sample for AST (liver parameter) in U/L 2 minutes
Secondary Blood sample Change in blood sample for alkaline phosphatase (liver parameter) in U/L 2 minutes
Secondary Blood sample Change in blood sample for bilirubin (liver parameter) in umol/L 2 minutes
Secondary MRI scan liver size Assessment of liver size 5 minutes
Secondary MR-elastography Assessment of liver fibrosis (assessed by MR-elastography) 5 minutes
Secondary MRI scan liver steatosis Assessment of liver steatosis 5 minutes
Secondary Ultrasound scan Additional assessment of liver size, fibrosis and steatosis 15 minutes
Secondary MRI scan Assessment of full body muscle size 15 minutes
Secondary MRI scan Assessment of muscle degeneration and subsequent fat replacement (using Dixon method to visualise fat in an optimal way) 15 minutes
Secondary Exercise test Change in time to cycle X km in minutes 7 minutes
Secondary Motorscore Change in motor function score, using the Motor Function Measurement (MFM-32). Assesses motor function in 3 domains, 32 two items in total. A higher score in each domain indicates better function. 20 minutes
See also
  Status Clinical Trial Phase
Completed NCT04851873 - Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) Phase 3
Completed NCT03223051 - Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy N/A
Completed NCT04335942 - Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor N/A
Recruiting NCT05794139 - Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy Phase 2
Not yet recruiting NCT00961103 - Motor Development and Orthoses in Spinal Muscular Atrophy (SMA) N/A
Completed NCT02003937 - Aerobic Training in Patients With Spinal Muscular Atrophy Type III N/A
Completed NCT00227266 - Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy Phase 2
Completed NCT00374075 - Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy Phase 1
Enrolling by invitation NCT05539456 - Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old
Recruiting NCT05779956 - Personalized Medicine for SMA: a Translational Project
Recruiting NCT03217578 - Neonatal Spinal Muscular Atrophy (SMA) Screening
Recruiting NCT03300869 - Natural History of Types 2 and 3 SMA in Taiwan
Completed NCT01703988 - An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Phase 1/Phase 2
Withdrawn NCT02235090 - Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting N/A
Completed NCT02123186 - Newborn Screening for Spinal Muscular Atrophy N/A
Completed NCT00756821 - A Pilot Study of Biomarkers for Spinal Muscular Atrophy N/A
Completed NCT00004771 - Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease Phase 2
Recruiting NCT05366465 - Quality of Life and Participation of the Adult With Spinal Muscular Atrophy in France
Recruiting NCT06310421 - Spinal Muscular Atrophy Neonatal Screening Program
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns